How to Save Money on Hemgenix in 2026: Copay Support, Patient Assistance, and Financial Programs

At approximately $3.5 million per one-time dose, Hemgenix (etranacogene dezaparvovec-drlb) is one of the most expensive medicines in the United States. That number can feel overwhelming — but for most patients with insurance, the out-of-pocket cost is dramatically different from the list price. Understanding how to navigate insurance, copay assistance, and patient support programs can bring your cost to near zero.

Here is a comprehensive guide to every available financial resource for Hemgenix in 2026.

What Does Hemgenix Actually Cost You With Insurance?

Hemgenix is billed under your medical benefit — not your pharmacy benefit. This is important because it means the drug cost counts toward your medical (not prescription) deductible and out-of-pocket maximum. For most patients:

Most commercially insured patients pay $0 out-of-pocket. CSL Behring's Copay Support Program (part of HEMGENIX Connect) covers eligible commercially insured patients' cost-sharing. Subject to program terms and conditions.

Medicare and Medicaid patients may have different coverage pathways. Hemgenix is covered under Medicare Part B (outpatient medical benefit) for eligible beneficiaries.

Uninsured patients should contact HEMGENIX Connect to discuss patient assistance options.

The HEMGENIX Connect Copay Support Program

HEMGENIX Connect is CSL Behring's comprehensive patient support program. To enroll, call 1-833-436-0021 (M–F 8AM–8PM ET). Once enrolled, you are assigned both a Patient Resource Navigator (for education and treatment journey support) and a CSL Case Manager (for insurance and financial coordination).

The Copay Support Program within HEMGENIX Connect may cover:

Out-of-pocket cost sharing for commercially insured patients (copays, coinsurance, deductibles related to the Hemgenix infusion)

Identification of the closest in-network administration center for your insurance plan

Support with insurance appeals if your initial authorization is denied

Enroll as early as possible — HEMGENIX Connect support begins from the moment you enroll, which gives your Case Manager more time to coordinate insurance and financial details before your treatment date.

How Insurance Prior Authorization Works for Hemgenix

Hemgenix requires prior authorization from your insurance plan before it can be administered. This is a medical PA (not a pharmacy PA), submitted by your treating hematologist or HTC. Insurers typically require:

Confirmed hemophilia B diagnosis with Factor IX activity levels documented

Evidence of current Factor IX prophylaxis use or qualifying bleeding history

Negative Factor IX inhibitor test results

Baseline liver function tests and liver ultrasound

Insurance approval typically takes 2–4 weeks. If your first request is denied, you have the right to appeal. Your HEMGENIX Connect Case Manager can help draft appeals with the appropriate clinical documentation.

Value-Based Contracting and Outcomes-Based Agreements

CSL Behring has worked with commercial payers on value-based agreements (VBAs) for Hemgenix — contracts in which the payer pays for the drug over time or receives rebates if the drug does not achieve certain clinical outcomes. This pricing model is designed to reduce the up-front financial barrier for payers while providing a path to coverage even at the $3.5 million list price.

From a patient perspective, VBAs are largely invisible — your coverage and out-of-pocket costs are still governed by your individual insurance plan. But they make it significantly more likely that your insurer will cover Hemgenix when your physician requests it.

Foundation and Non-Profit Assistance Programs

If you are uninsured, underinsured, or face coverage gaps, these organizations may provide financial assistance:

National Bleeding Disorders Foundation (NBDF): Offers patient assistance program directories and emergency financial support resources for people with bleeding disorders.

Hemophilia Federation of America (HFA) Helping Hands Program: Emergency financial assistance for people experiencing financial crisis due to a bleeding disorder (available once per year).

Coalition for Hemophilia B: Patient advocacy and support resources, including insurance navigation assistance.

Is Hemgenix Worth the Cost?

Annual prophylactic Factor IX infusions cost between $550,000 and $750,000 per year. A patient who receives Hemgenix at age 35 and achieves 15+ years of Factor IX production before potentially needing additional treatment could avoid $8–11 million or more in lifetime prophylaxis costs. ICER (the Institute for Clinical and Economic Review) found Hemgenix was cost-effective at prices between $5.2 million and $9.9 million — suggesting the $3.5 million price point may actually be a significant value for the healthcare system over time.

When you're ready to take the next step, medfinder.com can help you find which treatment centers near you currently have Hemgenix in stock. For tips on locating available supply, read How to Find Hemgenix in Stock Near You.